Autonomix Medical, Inc. financial data

Symbol
AMIX on Nasdaq
Location
21 Waterway Avenue, Suite 300, The Woodlands, TX
Fiscal year end
March 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 519 % -16.8%
Debt-to-equity 23.7 % -81.6%
Return On Equity -319 % +65.7%
Return On Assets -258 % +36.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.89M shares +498%
Common Stock, Shares, Outstanding 6.19M shares +438%
Entity Public Float 8.11M USD
Common Stock, Value, Issued 6K USD +500%
Weighted Average Number of Shares Outstanding, Basic 5.41M shares +338%
Weighted Average Number of Shares Outstanding, Diluted 13.8M shares +15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 6.56M USD +86.6%
General and Administrative Expense 10.4M USD +40.2%
Operating Income (Loss) -17M USD -55.1%
Nonoperating Income (Expense) 262K USD +186%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.7M USD -19%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.9M USD -3.6%
Earnings Per Share, Basic -4 USD/shares +57.5%
Earnings Per Share, Diluted -0.23 USD/shares -360%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.48M USD +45%
Other Assets, Current 416K USD +109%
Assets, Current 7.89M USD +47.4%
Property, Plant and Equipment, Net 16K USD -5.88%
Assets 7.93M USD +47.7%
Accounts Payable, Current 842K USD +46.7%
Accrued Liabilities, Current 645K USD -5.56%
Liabilities, Current 1.49M USD +18.3%
Other Liabilities, Noncurrent 4.97M USD
Liabilities 1.49M USD -36.5%
Retained Earnings (Accumulated Deficit) -61.2M USD -37.5%
Stockholders' Equity Attributable to Parent 6.45M USD +113%
Liabilities and Equity 7.93M USD +47.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.6M USD -40.6%
Net Cash Provided by (Used in) Financing Activities 2.06M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 6.19M shares +438%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -547K USD +70.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.22M USD +50.4%
Deferred Tax Assets, Valuation Allowance 5.72K USD +65.5%
Deferred Tax Assets, Gross 6.03K USD +74.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 761 USD -71.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 67.6M USD +42.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3K USD -93%
Deferred Tax Assets, Net of Valuation Allowance 306 USD
Interest Expense 33K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%